<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580488</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-008</org_study_id>
    <secondary_id>2011-005349-11</secondary_id>
    <nct_id>NCT01580488</nct_id>
  </id_info>
  <brief_title>A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris</brief_title>
  <official_title>A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different
      formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the
      psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Total Clinical Score From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score. Total Clinical Score range from 0 (all symptoms absent) to 9 (all symptoms severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Erythema From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Infiltration From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scaling From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Investigator's rating of the clinical appearance of scaling . Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lesion Thickness From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Change in total skin thickness measured by ultrasound from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skin Thickness From Baseline to Day 22</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Change in skin thickness - echo-poor band measured by ultrasound from baseline to end of treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B LEO 35299 20 mg/g cream</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C LEO 35299 20 mg/g cream</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E LEO 35299 10 mg/g solution</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F LEO 35299 10 mg/g solution</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex® ointment</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex® ointment vehicle</intervention_name>
    <description>once daily application, 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Following verbal and written information about the trial, the subject must provide
             signed and dated informed consent before any study related activities are carried out.

          2. Age 18 years or above.

          3. Males, or females of non-child bearing potential.

          4. Subjects with, in the opinion of the investigator, stable psoriasis based on Total
             Plaque Score evaluated at screening visit and at visit 2 (Baseline).

        Exclusion Criteria:

          1. Male subjects who are not willing to use a local contraception (such as condom) from
             the time of study entry and for three months following the last study drug
             application.

          2. Female subjects who are pregnant, of child-bearing potential or who are breast
             feeding.

          3. Systemic treatment with biological therapies (marketed or not marketed) with a
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2
             months(adalimumab, alefacept, infliximab), 4 months(ustekinumab) or 4 weeks/5
             half-lives (which-ever islonger) for experimental biological products prior to
             randomisation and during the study.

          4. Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, retinoids, immune suppressants) within
             the 4-week period prior to randomisation and during the study.

          5. Subjects using one of the following topical drugs for the treatment of psoriasis
             within the 4 week period prior to randomisation and during the study:

             - Potent or very potent (WHO group III-IV) corticosteroids.

          6. Subjects using of phototherapy within the following time periods prior to
             randomisation and during the study:

               -  PUVA (4 weeks)

               -  UVB (2 weeks)

          7. Subjects using one of the following topical drugs for the treatment of psoriasis
             within two weeks prior to randomisation and during the study:

               -  WHO group I-II corticosteroids (except if used for treatment of scalp and/or
                  facial psoriasis)

               -  Topical retinoids

               -  Vitamin D analogues

               -  Topical immunomodulators (e.g. macrolides)

               -  Anthracen derivatives

               -  Tar,

               -  Salicylic acid.

          8. Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular
             psoriasis

          9. Subjects with known/suspected disorders of calcium metabolism associated with
             hypercalcemia within the last 10 years, based on medical history and/or subject
             interview

         10. Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within the 4 week period prior to randomisation or longer, if the class of the
             substance requires a longer washout as defined above (e.g., biological treatments)

         11. Subjects with current participation in any other interventional clinical, based on
             interview of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière 06202 Nice Cedex 3, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD) - Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>November 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject first visit, start date: 24-Apr-2012 Last subject last visit, completion date: 05-Jun-2012</recruitment_details>
      <pre_assignment_details>Prior to randomisation, the subjects entered a washout phase of up to 21 days (if required) where antipsoriatic treatment and other relevant medications or treatments had to be discontinued as defined by the exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Each of the 24 subjects received all 6 investigational products on small dermal test sites: Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299 Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299 Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299 Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299 Topical ointment containing 50 mcg/g calcipotriol Topical ointment vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Total Clinical Score From Baseline to Day 22</title>
        <description>Investigator’s rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score. Total Clinical Score range from 0 (all symptoms absent) to 9 (all symptoms severe)</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Total Clinical Score From Baseline to Day 22</title>
          <description>Investigator’s rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score. Total Clinical Score range from 0 (all symptoms absent) to 9 (all symptoms severe)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.5"/>
                    <measurement group_id="O2" value="-1.9" spread="1.5"/>
                    <measurement group_id="O3" value="-1.5" spread="1.5"/>
                    <measurement group_id="O4" value="-1.8" spread="1.7"/>
                    <measurement group_id="O5" value="-4.0" spread="1.5"/>
                    <measurement group_id="O6" value="-3.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erythema From Baseline to Day 22</title>
        <description>Investigator’s rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythema From Baseline to Day 22</title>
          <description>Investigator’s rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.56"/>
                    <measurement group_id="O2" value="-0.67" spread="0.60"/>
                    <measurement group_id="O3" value="-0.54" spread="0.47"/>
                    <measurement group_id="O4" value="-0.70" spread="0.60"/>
                    <measurement group_id="O5" value="-1.09" spread="0.56"/>
                    <measurement group_id="O6" value="-1.07" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Infiltration From Baseline to Day 22</title>
        <description>Investigator’s rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Infiltration From Baseline to Day 22</title>
          <description>Investigator’s rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.59"/>
                    <measurement group_id="O2" value="-0.59" spread="0.54"/>
                    <measurement group_id="O3" value="-0.46" spread="0.58"/>
                    <measurement group_id="O4" value="-0.46" spread="0.66"/>
                    <measurement group_id="O5" value="-1.48" spread="0.55"/>
                    <measurement group_id="O6" value="-1.11" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Scaling From Baseline to Day 22</title>
        <description>Investigator’s rating of the clinical appearance of scaling . Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Scaling From Baseline to Day 22</title>
          <description>Investigator’s rating of the clinical appearance of scaling . Maximum score is 3 (most severe); minimum score is 0 (absent).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.49"/>
                    <measurement group_id="O2" value="-0.74" spread="0.60"/>
                    <measurement group_id="O3" value="-0.61" spread="0.64"/>
                    <measurement group_id="O4" value="-0.67" spread="0.60"/>
                    <measurement group_id="O5" value="-1.52" spread="0.59"/>
                    <measurement group_id="O6" value="-1.30" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lesion Thickness From Baseline to Day 22</title>
        <description>Change in total skin thickness measured by ultrasound from baseline to end of treatment</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lesion Thickness From Baseline to Day 22</title>
          <description>Change in total skin thickness measured by ultrasound from baseline to end of treatment</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.37"/>
                    <measurement group_id="O2" value="-0.18" spread="0.31"/>
                    <measurement group_id="O3" value="-0.22" spread="0.45"/>
                    <measurement group_id="O4" value="-0.24" spread="0.33"/>
                    <measurement group_id="O5" value="-0.36" spread="0.37"/>
                    <measurement group_id="O6" value="-0.38" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skin Thickness From Baseline to Day 22</title>
        <description>Change in skin thickness – echo-poor band measured by ultrasound from baseline to end of treatment</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O2">
            <title>C LEO 35299 20 mg/g</title>
            <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
          </group>
          <group group_id="O3">
            <title>E LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O4">
            <title>F LEO 35299 10 mg/g</title>
            <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
          </group>
          <group group_id="O5">
            <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
            <description>Topical ointment containing 50 mcg/g calcipotriol</description>
          </group>
          <group group_id="O6">
            <title>Daivonex® Ointment</title>
            <description>Topical ointment vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skin Thickness From Baseline to Day 22</title>
          <description>Change in skin thickness – echo-poor band measured by ultrasound from baseline to end of treatment</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.56"/>
                    <measurement group_id="O2" value="-0.29" spread="0.47"/>
                    <measurement group_id="O3" value="-0.24" spread="0.71"/>
                    <measurement group_id="O4" value="-0.40" spread="0.51"/>
                    <measurement group_id="O5" value="-0.57" spread="0.57"/>
                    <measurement group_id="O6" value="-0.49" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>B LEO 35299 20 mg/g</title>
          <description>Topical cream formulation &quot;B&quot; containing 20 mg/g LEO 35299</description>
        </group>
        <group group_id="E2">
          <title>C LEO 35299 20 mg/g</title>
          <description>Topical cream formulation &quot;C&quot; containing 20 mg/g LEO 35299</description>
        </group>
        <group group_id="E3">
          <title>E LEO 35299 10 mg/g</title>
          <description>Topical solution formulation &quot;E&quot; containing 10 mg/g LEO 35299</description>
        </group>
        <group group_id="E4">
          <title>F LEO 35299 10 mg/g</title>
          <description>Topical solution formulation &quot;F&quot; containing 10 mg/g LEO 35299</description>
        </group>
        <group group_id="E5">
          <title>Daivonex® Ointment: Calcipotriol 50 Mcg/g Ointment</title>
          <description>Topical ointment containing 50 mcg/g calcipotriol</description>
        </group>
        <group group_id="E6">
          <title>Daivonex® Ointment</title>
          <description>Topical ointment vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor is entitled to review and comment on publications prior to submission or presentation. Upon request of the sponsor, the investigator shall delay publication or presentation to allow for protection of the sponsors inventions and other intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an exploratory study in which each of the 24 subjects received all 6 treatments on 2 cm diameter dermal test sites. Regarding Adverse Events, only local dermal reactions could be potentially attributed to a specific treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

